Processing...
Clinical Trials for Uterine Cancer
Search
Search
There are 163 active trials for advanced/metastatic uterine cancer.
Click on a trial to see more information.
163 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with unresectable, metastatic, or recurrent dMMR/MSI-H solid tumors receive oral GSK5460025 monotherapy, an investigational nucleotide excision repair–targeting agent that causes repair-pathway-dependent DNA damage. Dose expansion is limited to colorectal or endometrial cancer after 1–3 systemic therapy lines, including an immune checkpoint inhibitor.
ClinicalTrials.gov ID: NCT07213609
TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors refractory to standard therapy or without proven effective options receive KIVU-107, an investigational PTK7-directed antibody-drug conjugate carrying an exatecan/topoisomerase I inhibitor payload. The study includes dose escalation followed by expansion at the recommended dose, with eligibility requiring measurable disease, ECOG 0–1, and adequate organ function.
ClinicalTrials.gov ID: NCT07229313
TrialFetch AI summary: Adults with ECOG 0–1 and measurable locally advanced/metastatic solid tumors co-expressing B7-H3 and PTK7, after progression/intolerance to prior therapy or lacking standard options, including NSCLC, ESCC, endometrial, ovarian, HNSCC, TNBC, colorectal, and CRPC. All participants receive IDE034, an investigational bispecific B7-H3/PTK7 antibody–drug conjugate with a topoisomerase I inhibitor payload, in dose-escalation and expansion cohorts.
ClinicalTrials.gov ID: NCT07503808
TrialFetch AI summary: Open-label dose-escalation/expansion study of oral RGT-490 monotherapy, a selective mutant PI3Kα inhibitor, in adults with locally advanced unresectable or metastatic solid tumors harboring activating PIK3CA mutations after at least one prior therapy. Expansion focuses on HR+/HER2− advanced breast cancer; patients with prior PI3Kα inhibitor exposure or diabetes requiring antihyperglycemic medication are excluded.
ClinicalTrials.gov ID: NCT07524322
TrialFetch AI summary: Open-label dose-escalation study of oral KST-6051, an investigational pan-KRAS inhibitor targeting both active and inactive KRAS conformations, in adults with locally advanced unresectable or metastatic KRAS-mutant solid tumors including NSCLC, pancreatic, colorectal, and other cancers. Patients must have progressed after or been intolerant of standard therapy, have ECOG 0-1 and measurable disease, with no prior/current RAS/KRAS inhibitor therapy or CNS metastases.
ClinicalTrials.gov ID: NCT07458347
TrialFetch AI summary: Adults with ECOG 0–1 and refractory/relapsed locally advanced unresectable or metastatic solid tumors, including post–PD-1/PD-L1 treated RCC, HCC, gastroesophageal cancer, and endometrial cancer, receive CTX-10726 monotherapy IV every 2 weeks. CTX-10726 is an investigational tetravalent bispecific antibody targeting PD-1 and VEGF-A to combine checkpoint blockade with anti-angiogenic activity.
ClinicalTrials.gov ID: NCT07419841
TrialFetch AI summary: Adults with advanced/metastatic PTK7-expressing solid tumors, including non-squamous EGFR-wild-type NSCLC, platinum-resistant ovarian cancer, and endometrial carcinoma, receive HWK-007 IV every 3 weeks. HWK-007 is an investigational PTK7-directed antibody–drug conjugate delivering a topoisomerase I inhibitor payload, with dose escalation/expansion focused on safety, dose selection, pharmacokinetics, immunogenicity, and preliminary antitumor activity.
ClinicalTrials.gov ID: NCT07444814
TrialFetch AI summary: First-in-human dose-escalation trial of injectable BI 3820768, an investigational immune-directed anticancer biologic with limited public target/mechanism details, given weekly for two 3-week cycles then every 3 weeks. Enrolls ECOG 0–1 adults with advanced relapsed/refractory germ cell tumors, endometrial cancer, or ovarian cancer after standard options; endometrial and ovarian cohorts require centrally confirmed target-positive tumors.
ClinicalTrials.gov ID: NCT07306559
TrialFetch AI summary: Adults with advanced/metastatic solid tumors, initially ovarian cancer and endometrial carcinoma, receive IV HWK-016, a first-in-human MUC16-directed antibody–drug conjugate carrying a topoisomerase I inhibitor payload. Ovarian cancer cohorts may also receive HWK-016 combined with bevacizumab, with dose escalation/expansion focused on safety, recommended dose, pharmacokinetics, and preliminary antitumor activity.
ClinicalTrials.gov ID: NCT07470853
TrialFetch AI summary: Adults with unresectable or metastatic advanced solid tumors, particularly MSI-H/dMMR tumors, receive oral EIK1005, a Werner syndrome helicase inhibitor intended to exploit synthetic lethality in MSI-H cancers, after progression/intolerance of standard therapy or in dose-optimization cohorts. The study tests EIK1005 monotherapy and dose escalation of EIK1005 plus pembrolizumab in MSI-H/dMMR advanced solid tumors.
ClinicalTrials.gov ID: NCT07262619